How many drugs treat Anaphylaxis Adjunct?

Drug Landscape tracks 4 marketed treatments for Anaphylaxis Adjunct (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anaphylaxis-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anaphylaxis Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anaphylaxis Adjunct (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anaphylaxis Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Pyribenzamin	TRIPELENNAMINE CITRATE	Novartis	tripelennamine	Histamine H1 receptor	1948-01-01
Clemastin	Clemastin	Technical University of Munich		5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Anaphylaxis Adjunct
Novartis · 2 drugs in Anaphylaxis Adjunct
GSK · 1 drug in Anaphylaxis Adjunct
Technical University of Munich · 1 drug in Anaphylaxis Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anaphylaxis Adjunct:

Cite this brief

Drug Landscape (2026). Anaphylaxis Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anaphylaxis-adjunct. Accessed 2026-06-10.

Anaphylaxis Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing